Soleno Therapeutics(SLNO)

产业链观察04-29 23:20

#药闻简讯# $Soleno Therapeutics(SLNO)$ 获得 DCCR（二氮嗪胆碱）缓释片治疗普拉德-威利综合征 （PWS） 的突破性疗法认定查看全文

其他

Soleno Therapeutics(SLNO)04-23 05:15

$Soleno Therapeutics(SLNO)$ ARS Annual Report to Security Holders Accession Number: 0000950170-24-046496  Act: 34  Size: 606 KB 网页链接查看全文

持股变动声明

Soleno Therapeutics(SLNO)06-11 08:55

$Soleno Therapeutics(SLNO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-016312  Size: 5 KB 网页链接查看全文

首次持股声明

Soleno Therapeutics(SLNO)05-01 06:05

$Soleno Therapeutics(SLNO)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001415889-24-011794  Size: 13 KB 网页链接查看全文

招股说明书

Soleno Therapeutics(SLNO)05-03 04:05

$Soleno Therapeutics(SLNO)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-24-129348  Act: 33  Size: 1 MB 网页链接查看全文

当期报告

Soleno Therapeutics(SLNO)04-30 04:15

$Soleno Therapeutics(SLNO)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001193125-24-122237  Act: 34  Size: 161 KB 网页链接查看全文

招股说明书

Soleno Therapeutics(SLNO)05-07 05:05

$Soleno Therapeutics(SLNO)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-24-132008  Act: 33  Size: 1 MB 网页链接查看全文

当期报告

Soleno Therapeutics(SLNO)05-10 18:05

$Soleno Therapeutics(SLNO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001193125-24-135478  Act: 34  Size: 226 KB 网页链接查看全文

当期报告

Soleno Therapeutics(SLNO)06-21 04:25

$Soleno Therapeutics(SLNO)$ 8-K Current report, item 1.01 Accession Number: 0001193125-24-164463  Act: 34  Size: 144 KB 网页链接查看全文

持股变动声明

Soleno Therapeutics(SLNO)07-04 06:05

$Soleno Therapeutics(SLNO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-019266  Size: 7 KB 网页链接查看全文

刘灵巧2019-03-15 05:59

$Soleno Therapeutics(SLNO)$ 黑马股 1.50进场查看全文

usbiostock2018-07-30 22:25

$Soleno Therapeutics, Inc.(SLNO)$ FDA授予DCCR“快速通道”认定，用于治疗普拉德-威利综合征（PWS），该产品线目前正处理临床3期阶段。查看全文

sjGold2018-06-23 01:15

$Soleno Therapeutics, Inc.(SLNO)$ 罗斯资本发起了对Soleno Therapeutics，Inc.（纳斯达克股票代码：SLNO）的买入评级。 Soleno Therapeutics的价格目标定为14美元。 Soleno Therapeutics周四收报2.33美元。查看全文

魔法学徒2017-12-22 22:12

$Soleno Therapeutics, Inc.(SLNO)$减肥的查看全文

持股变动声明

$Soleno Therapeutics(SLNO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-019266  Size: 7 KB 网页链接

持股变动声明

$Soleno Therapeutics(SLNO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-019268  Size: 7 KB 网页链接

持股变动声明

$Soleno Therapeutics(SLNO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-019271  Size: 7 KB 网页链接

持股变动声明

$Soleno Therapeutics(SLNO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-019269  Size: 7 KB 网页链接

证券出售报告

$Soleno Therapeutics(SLNO)$ 144 Report of proposed sale of securities Accession Number: 0001972362-24-000940  Act: 33  Size: 4 KB 网页链接

当期报告

$Soleno Therapeutics(SLNO)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001193125-24-172238  Act: 34  Size: 161 KB 网页链接

当期报告

$Soleno Therapeutics(SLNO)$ 8-K Current report, item 1.01 Accession Number: 0001193125-24-164463  Act: 34  Size: 144 KB 网页链接

持股变动声明

$Soleno Therapeutics(SLNO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-016311  Size: 5 KB 网页链接

持股变动声明

$Soleno Therapeutics(SLNO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-016308  Size: 5 KB 网页链接

持股变动声明

$Soleno Therapeutics(SLNO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-016310  Size: 5 KB 网页链接